GUCY1A1
ENSG00000164116
Target class
Enzyme
Chromosome
4
Approved drugs
8
Clinical candidates (approved and in development)
14
- Approved drugs
- 8
- Clinical candidates (approved and in development)
- 14
- Chemical probe available
- No
- Other names
- GC-SA3
- Target name
- GUCY1A1
- Gene name
- Guanylate cyclase 1 soluble subunit alpha 1
- Gene symbol
- GUCY1A1
- Protein name
- Guanylate cyclase soluble subunit alpha-1 (GCS-alpha-1) (EC 4.6.1.2) (Guanylate cyclase soluble subunit alpha-3) (GCS-alpha-3) (Soluble guanylate cyclase large subunit)
- GUC1A3
- GUCY1A3
- Gene biotype
- Protein coding
- Gene family
- Soluble guanylate cyclases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 39.69
- Tissue specificity (Gini)
- 0.483
- Tissue specificity (tau)
- 0.818
- KEGG gene identifiers
- hsa:2982
- Protein interaction confidence
- 0.829464
- Protein interaction partners
- 28
- R-HSA-392154
- R-HSA-445355
- End position
- 155737059
- Start position
- 155666707
- Chromosome
- 4
- Strand
- Forward
- Cytoplasm .
- Nucleoplasm
- Tissue specificity (tau)
- 0.817876
- Expression inequality (Gini)
- 0.482921
Expression in transcripts per million
- Colon - Sigmoid
- 39.69
- Artery - Coronary
- 28.98
- Artery - Tibial
- 24.04
- Artery - Aorta
- 23.71
- Esophagus - Gastroesophageal Junction
- 19.92
Expression in transcripts per million
- Colon - Sigmoid39.69
- Artery - Coronary28.98
- Artery - Tibial24.04
- Artery - Aorta23.71
- Esophagus - Gastroesophageal Junction19.92
- Prostate19.72
- Esophagus - Muscularis15.63
- Lung14.79
- Colon - Transverse13.65
- Uterus12.7
- Breast - Mammary Tissue12.26
- Adipose - Subcutaneous10.54
- Kidney - Medulla10.22
- Adipose - Visceral (Omentum)9.82
- Cervix - Endocervix9.44
- Thyroid9.02
- Heart - Atrial Appendage8.44
- Fallopian Tube8.41
- Cervix - Ectocervix8.19
- Vagina7.31
- Heart - Left Ventricle7.31
- Minor Salivary Gland6.88
- Small Intestine - Terminal Ileum6.78
- Brain - Nucleus accumbens (basal ganglia)6.74
- Nerve - Tibial6.48
And 29 more, listed on the interactive page.
- GO:0006182
- GO:0038060
- GO:0005654
- GO:0005829
- GO:0008074
- GO:0004383
- GO:0005515
Related records
Trials (610)
- : Vascular Function in Health and Disease
- "Lignocaine vs GTN Ointment for Postoperative Pain After Hemorrhoidectomy")
- 1H Magnetic Resonance Spectroscopy in Migraine Patients
- 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
- A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
- A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects
- A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis
- A Cohort Prospective Study of Predictors Influencing the Quality of Visualization of the Operating Field During Orthognathic Surgery
- A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control
- A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers
- A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis
- A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
- A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
- A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
- A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
- A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
- A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
- A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia
- A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
- A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately
Drugs (16)
- Ataciguat Soluble guanylate cyclase activator
- Cinaciguat Soluble guanylate cyclase activator
- Isosorbide dinitrate Soluble guanylate cyclase activator
- Isosorbide mononitrate Soluble guanylate cyclase activator
- Methylene blue anhydrous Soluble guanylate cyclase inhibitor
- Methylene blue cation Soluble guanylate cyclase inhibitor
- Nitric oxide Soluble guanylate cyclase activator
- Nitroglycerin Soluble guanylate cyclase activator
- Nitroprusside Soluble guanylate cyclase activator
- Olinciguat Soluble guanylate cyclase positive allosteric modulator
- Pentaerythritol tetranitrate Soluble guanylate cyclase activator
- Praliciguat Soluble guanylate cyclase activator
- Riociguat Soluble guanylate cyclase positive allosteric modulator
- Runcaciguat Soluble guanylate cyclase activator
- Sodium nitroprusside Soluble guanylate cyclase activator
- Vericiguat Soluble guanylate cyclase activator